Effects of Intravitreal Bevacizumab Therapy in Patients with Proliferative Diabetic Retinopathy

Giuliana Ribeiro de Carvalho,1,2 Vagner Loduca Lima,2 Glaucia Luciano da Veiga,1 Fernando Adami,3 Beatriz da Costa Aguiar Alves,1 Edimar Cristiano Pereira,4 David Feder,1 Fernando Luiz Affonso Fonseca1,4 1Clinical Analysis Laboratory, Centro Universitário Saúde ABC/Faculdade De...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ribeiro de Carvalho G, Loduca Lima V, da Veiga GL, Adami F, da Costa Aguiar Alves B, Cristiano Pereira E, Feder D, Fonseca FLA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	diabetic retinopathy bevacizumab macular edema Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/a69d47279ca4448b90cd40a7cfd3b4d8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a69d47279ca4448b90cd40a7cfd3b4d8
record_format	dspace
spelling	oai:doaj.org-article:a69d47279ca4448b90cd40a7cfd3b4d82021-12-02T08:46:51ZEffects of Intravitreal Bevacizumab Therapy in Patients with Proliferative Diabetic Retinopathy1178-7007https://doaj.org/article/a69d47279ca4448b90cd40a7cfd3b4d82020-09-01T00:00:00Zhttps://www.dovepress.com/effects-of-intravitreal-bevacizumab-therapy-in-patients-with-prolifera-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Giuliana Ribeiro de Carvalho,1,2 Vagner Loduca Lima,2 Glaucia Luciano da Veiga,1 Fernando Adami,3 Beatriz da Costa Aguiar Alves,1 Edimar Cristiano Pereira,4 David Feder,1 Fernando Luiz Affonso Fonseca1,4 1Clinical Analysis Laboratory, Centro Universitário Saúde ABC/Faculdade De Medicina Do ABC, Santo André, Brazil; 2Ophthalmology Discipline, Centro Universitário Saúde ABC-Faculdade de Medicina do ABC, Santo André, Brazil; 3Epidemiology Department, Centro Universitário Saúde ABC/Faculdade De Medicina Do ABC, Santo André, Brazil; 4Pharmaceutical Sciences Department, Universidade Federal De São Paulo, Diadema, BrazilCorrespondence: Fernando Luiz Affonso Fonseca 2000, Lauro Gomes Avenue, Santo Andre CEP: 09060-650, BrazilTel +5511 4993-5488Email profferfonseca@gmail.comIntroduction: Diabetes mellitus (DM) stands out as one of the chronic diseases with the highest morbidity and mortality rates worldwide. Among the many complications of DM, diabetic retinopathy (DR) is one of the causes of blindness in patients aged between 20 and 64 years. At least 90% of the new cases showed to have the retinal structure and function restored when proper treatment was provided.Aim: To evaluate the efficacy of the antiangiogenic bevacizumab in the treatment of DR according not only to the clinical laboratory parameters for glycated hemoglobin (HbA1C) and capillary glycemia but also to the ophthalmological parameters for optical coherence tomography (OCT) and best-corrected visual acuity (BCVA).Patients and Methods: A total of 11 individuals were included and followed up for 12 months after 3 administrations of bevacizumab.Results: Upon associating the ophthalmological and laboratory variables throughout the treatment, no significant alterations could be seen regarding the analyzed variables. However, it was observed that HbA1c values and the total leukocyte count negatively interfered with the treatment response.Conclusion: The current study showed that HbA1c values and the amount of leukocytes negatively interfere with the therapeutic response. Therefore, laboratory analyses of these parameters are recommended for diabetic patients undergoing the above-mentioned treatment.Keywords: diabetic retinopathy, bevacizumab, macular edemaRibeiro de Carvalho GLoduca Lima Vda Veiga GLAdami Fda Costa Aguiar Alves BCristiano Pereira EFeder DFonseca FLADove Medical Pressarticlediabetic retinopathybevacizumabmacular edemaSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 3149-3155 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	diabetic retinopathy bevacizumab macular edema Specialties of internal medicine RC581-951
spellingShingle	diabetic retinopathy bevacizumab macular edema Specialties of internal medicine RC581-951 Ribeiro de Carvalho G Loduca Lima V da Veiga GL Adami F da Costa Aguiar Alves B Cristiano Pereira E Feder D Fonseca FLA Effects of Intravitreal Bevacizumab Therapy in Patients with Proliferative Diabetic Retinopathy
description	Giuliana Ribeiro de Carvalho,1,2 Vagner Loduca Lima,2 Glaucia Luciano da Veiga,1 Fernando Adami,3 Beatriz da Costa Aguiar Alves,1 Edimar Cristiano Pereira,4 David Feder,1 Fernando Luiz Affonso Fonseca1,4 1Clinical Analysis Laboratory, Centro Universitário Saúde ABC/Faculdade De Medicina Do ABC, Santo André, Brazil; 2Ophthalmology Discipline, Centro Universitário Saúde ABC-Faculdade de Medicina do ABC, Santo André, Brazil; 3Epidemiology Department, Centro Universitário Saúde ABC/Faculdade De Medicina Do ABC, Santo André, Brazil; 4Pharmaceutical Sciences Department, Universidade Federal De São Paulo, Diadema, BrazilCorrespondence: Fernando Luiz Affonso Fonseca 2000, Lauro Gomes Avenue, Santo Andre CEP: 09060-650, BrazilTel +5511 4993-5488Email profferfonseca@gmail.comIntroduction: Diabetes mellitus (DM) stands out as one of the chronic diseases with the highest morbidity and mortality rates worldwide. Among the many complications of DM, diabetic retinopathy (DR) is one of the causes of blindness in patients aged between 20 and 64 years. At least 90% of the new cases showed to have the retinal structure and function restored when proper treatment was provided.Aim: To evaluate the efficacy of the antiangiogenic bevacizumab in the treatment of DR according not only to the clinical laboratory parameters for glycated hemoglobin (HbA1C) and capillary glycemia but also to the ophthalmological parameters for optical coherence tomography (OCT) and best-corrected visual acuity (BCVA).Patients and Methods: A total of 11 individuals were included and followed up for 12 months after 3 administrations of bevacizumab.Results: Upon associating the ophthalmological and laboratory variables throughout the treatment, no significant alterations could be seen regarding the analyzed variables. However, it was observed that HbA1c values and the total leukocyte count negatively interfered with the treatment response.Conclusion: The current study showed that HbA1c values and the amount of leukocytes negatively interfere with the therapeutic response. Therefore, laboratory analyses of these parameters are recommended for diabetic patients undergoing the above-mentioned treatment.Keywords: diabetic retinopathy, bevacizumab, macular edema
format	article
author	Ribeiro de Carvalho G Loduca Lima V da Veiga GL Adami F da Costa Aguiar Alves B Cristiano Pereira E Feder D Fonseca FLA
author_facet	Ribeiro de Carvalho G Loduca Lima V da Veiga GL Adami F da Costa Aguiar Alves B Cristiano Pereira E Feder D Fonseca FLA
author_sort	Ribeiro de Carvalho G
title	Effects of Intravitreal Bevacizumab Therapy in Patients with Proliferative Diabetic Retinopathy
title_short	Effects of Intravitreal Bevacizumab Therapy in Patients with Proliferative Diabetic Retinopathy
title_full	Effects of Intravitreal Bevacizumab Therapy in Patients with Proliferative Diabetic Retinopathy
title_fullStr	Effects of Intravitreal Bevacizumab Therapy in Patients with Proliferative Diabetic Retinopathy
title_full_unstemmed	Effects of Intravitreal Bevacizumab Therapy in Patients with Proliferative Diabetic Retinopathy
title_sort	effects of intravitreal bevacizumab therapy in patients with proliferative diabetic retinopathy
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/a69d47279ca4448b90cd40a7cfd3b4d8
work_keys_str_mv	AT ribeirodecarvalhog effectsofintravitrealbevacizumabtherapyinpatientswithproliferativediabeticretinopathy AT loducalimav effectsofintravitrealbevacizumabtherapyinpatientswithproliferativediabeticretinopathy AT daveigagl effectsofintravitrealbevacizumabtherapyinpatientswithproliferativediabeticretinopathy AT adamif effectsofintravitrealbevacizumabtherapyinpatientswithproliferativediabeticretinopathy AT dacostaaguiaralvesb effectsofintravitrealbevacizumabtherapyinpatientswithproliferativediabeticretinopathy AT cristianopereirae effectsofintravitrealbevacizumabtherapyinpatientswithproliferativediabeticretinopathy AT federd effectsofintravitrealbevacizumabtherapyinpatientswithproliferativediabeticretinopathy AT fonsecafla effectsofintravitrealbevacizumabtherapyinpatientswithproliferativediabeticretinopathy
_version_	1718398381823361024

Effects of Intravitreal Bevacizumab Therapy in Patients with Proliferative Diabetic Retinopathy

Ejemplares similares